GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » EV-to-FCF

Actavia Life Sciences (Actavia Life Sciences) EV-to-FCF : -202.21 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Actavia Life Sciences's Enterprise Value is $13.35 Mil. Actavia Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.07 Mil. Therefore, Actavia Life Sciences's EV-to-FCF for today is -202.21.

The historical rank and industry rank for Actavia Life Sciences's EV-to-FCF or its related term are showing as below:

RASP' s EV-to-FCF Range Over the Past 10 Years
Min: -788.75   Med: 0   Max: 0
Current: -202.21

RASP's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs RASP: -202.21

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Actavia Life Sciences's stock price is $0.0169. Actavia Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.001. Therefore, Actavia Life Sciences's PE Ratio for today is At Loss.


Actavia Life Sciences EV-to-FCF Historical Data

The historical data trend for Actavia Life Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences EV-to-FCF Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -113.45 -23.99 -16.40 -7.59 -1,730.25

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.49 -94.33 -1,730.25 -113.89 -94.64

Competitive Comparison of Actavia Life Sciences's EV-to-FCF

For the Biotechnology subindustry, Actavia Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's EV-to-FCF falls into.



Actavia Life Sciences EV-to-FCF Calculation

Actavia Life Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=13.346/-0.066
=-202.21

Actavia Life Sciences's current Enterprise Value is $13.35 Mil.
Actavia Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actavia Life Sciences  (OTCPK:RASP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Actavia Life Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0169/-0.001
=At Loss

Actavia Life Sciences's share price for today is $0.0169.
Actavia Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.001.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Actavia Life Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines